The NK cell/Anti-PD-1 signature devised in melanoma models also strongly correlated with IL2RB (Supplementary Figure S5C and D, R = 0.77, P < 0.0001 and R = 0.77, P < 0.0001) as did the pembrolizumab signature from the KEYNOTE-001 phase I clinical trial (Supplementary Figure S5E and F, R = 0.88, P < 0.0001 and R = 0.84, P < 0.0001) (37,38). The gene discussed is PDCD1; the disease is melanoma.